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Endonuclease restrictionBackground: Recent studies have shown that somatic mutations in DNA methyltransferase (DNMT3A)
might affect the prognosis of AML.
Objective: The aim of this work was to investigate the frequency and prognostic impact of the most fre-
quent mutation of DNMT3A, R882H mutation in AML using simple and rapid molecular techniques.
Patients and methods: We have used allele-specific blocker (ASB-PCR) and endonuclease restriction for
the detection of DNMT3A R882H mutation in 56 adult patients with AML.
Results: DNMT3A R882H mutation was detected in 7/56 (12.5%) of patients. R882H mutation positive
patients were older compared to the wild-type AML (p = 0.08). No association was found with initial lab-
oratory parameters including white blood cells (WBC), hemoglobin (HGB) and Bone marrow (BM) blasts
(p > 0.05). Thirty-two patients (57.1%) achieved complete remission (CR), 11/56 (19.6%) died before day
28 induction death (ID) and 13/56 (23.2%) had resistant disease (RD). DNMT3A R882H positive patients
were not different regarding the response to induction chemotherapy (CR) compared to the negative
group (wild-type) (p > 0.05). Median follow-up period for all patients was 1.6 months, Overall survival
(OS) was 65%, and the median was 9.89 months. OS of DNMT3A positive patients was not statistically sig-
nificant compared to wild-type patients (p = 0.09). Disease free survival (DFS) was 54.6% for all patients,
with no difference between wild and mutants (0.59) patients.
Conclusion: DNMT3A R882H is a frequent mutation in adult de novo AML. The frequency of the mutation
tends to increase with age. The two methods used in the study are easy to interpret and are recom-
mended for rapid detection of the mutation required for risk stratification.
 2018 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
DNA methyltransferase controls methylation of DNA; DNMT3A,
DNMT3B, DNMT3L, DNMT1 and DNMT2 [1] DNMTs catalyze the
addition of a methyl group to C5 of cytosine in DNA forming 5-
methyl cytosine [2]. DNA methylation occurs at cytosine in any
context of the genome, however locus-specific modification at
the CpG dinucleotide 5¢ end is common. Aberrant methylation in
cancer cells occurs in the form of global hypomethylation or hyper-
methylation at promotor associated CpGs clusters [3]. The 130 kDa
protein DNMT3A is encoded by 34 exons on 2p23 chromosome
with two transcripts, Dnmt3a1 and Dnmt3a3 [2]. Methylation
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ferases and histone deacetylases which are needed for regulation
of gene expression. [1].
DNMT3A mutations are distributed among both myeloid and
lymphoid malignancies. In the myeloid group, mutations are
detected in AML, Myeloproliferative neoplasms (MPN), myelodys-
plastic syndromes (MDSs) and chronic myelomonocytic leukemia
(CMML) [4–6]. Across the lymphoid group, mutations are detected
in T cell leukemias and lymphomas. Most of mutations are found in
adult AML (14–35%) followed by T-ALL (17%) [2].
AML is classified into three major groups; AML with recurrent
cytogenetic abnormalities, AML with myelodysplasia related
changes and therapy related AML. Risk stratification of AML is
based on cytogenetics and molecular abnormalities. Patients with
normal cytogenetics (CN-AML) are classified with the
intermediate-risk group. However, incorporation of molecular
abnormalities to the risk classification has improved the risk of
CN-AML from the intermediate to the favorable risk group for
patients with mutated nuclophosmine (NPM1) or biallelic enhan-
cer binding protein alpha (CEBPA) in the absence of FLT3 internal
tandem duplication (FLT-3-ITD) mutation [7].
Somatic mutations of DNMT3A are classified into R882 versus
non R882. The R882 mutations constitute 60% of all DNMT3A
mutations and affect the methyltransferase domain of the DNMT3
protein. Mutations at R882 are missense mutations and affect the
amino acid at R882 with different variants: R882H, R882C,
R882P, and R882S. The non R882 group includes, nonsense and
frame shift mutations across the DNMT3A gene [8,9]. DNMT3A
mutations are usually heterozygous. Homozygous bi-allelic muta-
tions are confined to the T-lymphoid R882 and to the non-R882
mutations [2,5,9].
There is still some controversy regarding the prognostic impact
of DNMT3A R882H mutations on adult AML [8–10]. Some reports
have studied the prognostic effect of the association between
DNMT3A mutation and other mutations such as NPM1 and FLT3-
ITD [2].
Direct sequencing has been used frequently in the past few
years, for the detection of somatic mutations, although it is very
informative but expensive when compared to other molecular
techniques.
The aim of this study was to use simple and rapid molecular
techniques; endonuclease restriction analysis and ASB-PCR, to
investigate the frequency and prognostic impact of DNMT3A
R882H mutation in de novo adult AML.2. Patients and methods
2.1. Patients
In a period of 6 months, between January and June 2016, initial
bone marrow samples from 56 Adults with de novo AML patients
18–60 years, were recruited for this study. All patients were
referred to the outpatient clinic of the National Cancer Institute
(NCI), Cairo University. Patients with secondary or previously trea-
ted AML and patients with AML (M3) positive for t (15;17) were
excluded from the study. Diagnosis of AML was established accord-
ing to the standard morphology, cytochemistry, and French Amer-
ican British (FAB) criteria [11]. The work has been carried out in
accordance with the Code of Ethics of the World Medical Associa-
tion (Declaration of Helsinki) for experiments in humans and was
approved by the ethical committee of the NCI (IRP number
2015160282).
All patients received the standards 3 and 7 protocols AML pro-
tocol of the NCI. Induction chemotherapy consisted of adriamycin
30 mg/m2 for 3 days and cytosine arabinoside (AraC) 100 mg/m2by continuous infusion for 7 days. Further treatment of AML
patients was according to their risk group [7].
2.2. End points
CR was defined as a normocellular BM containing less than 5%
blasts. Failure of CR as either, partial remission (5%–15%) blasts
or resistant disease (RD) (>15% blasts in the BM). Deaths within
30 days of entry were classified as induction death (ID). OS end
points were measured from the date of diagnosis to death or last
follow-up. For patients achieving CR, DFS points were measured
from the date of documented CR to relapse.
2.3. Methods
2.3.1. DNA extraction
DNA was extracted from BM samples using the QiaAmp DNA
extraction Mini kit (Qiagen, Hilden, Germany) according to manu-
facturer instructions. Genomic DNA was examined for quality and
quantity on Nanodrop spectrophotometer.
2.3.2. Analysis of DNMT3A R882H
DNMT3A R882H mutation is the most frequent R882H mutation
in AML. Two primers were used for amplification of exon 23
(NM_022552.4). Reaction mixture and primers were described pre-
viously, [12]. PCR products were analyzed on standard 1.5% agar-
ose gels, expected PCR fragment after amplification was 444 bp.
For mutation detection, 10ul of PCR product was digested by 10
units of Fnu4HI restriction enzyme (Thermo Scientific) and incu-
bated overnight at 37 C. The Digested product was separated by
agarose gel electrophoresis and stained with ethidium bromide.
Custom labeled primers, probes, and blocker (Applied Biosys-
tem) were prepared for the ASB-PCR. The PCR assay was performed
on step one real-time PCR machine (Applied Biosystems). The
sequence of primers, probes, and blocker was described previously
[13]. One positive and one negative control samples were added to
each run. The analytic specificity and sensitivity of ASB-PCR were
tested. Sanger-based sequencing was performed on 3500 genetic
analyzer, (Applied Biosystem) to confirm all positive cases [14].
2.4. Statistical methods
SPSS package version 17.0 was used for data management.
Mann-Whitney was used to compare numerical variable in two
independent groups. Chi-square tested proportion independence.
Kaplan-Meier method was used to estimate survival and log-rank
compared curves. P values 0.05 were considered significant.
3. Results
3.1. Characterization of the patients
We examined 56 patients with de novo AML. Median age was
38 (19–60) years, male to female ratio was 1:1. Of the examined
patients, 13 (23%) presented with hepatomegaly, 6 (10.7%) with
splenomegaly, and 8 (14%) with lymphadenopathy. FLT3-ITDmuta-
tion was detected in 12 (21.4%) patients and FLT3-TKD was
detected in 4 (7.5%) patients. The median follow-up for survival
was 1.69 (0–11.7) months. The cumulative OS at 6 months was
(65%). Initial patient’s characteristics are shown in Table 1.
3.2. DNMT3A R882H mutation in AML
Restriction endonuclease analysis, using Fnu4HI enzyme is rep-





Mean SD 39.63 ± 11.87





Mean ± SD 55.3 ± 67.16
Median (range) 24 (0.3–301)
Hb (g/dl)
Mean ± SD 7.1 ± 1.7
Median (range) 7 (3.1–11.8)
Platelets (X109/L)
Mean ± SD 65.7 ± 59.96
Median (range) 40 (10–246)
BM Blasts
Mean ± SD 52.95 ± 26.80
Median (range) 51 (62–98)








FLT3-ITD, n (%) 12 (21.4)







Cumulative at 6 months, % 56
DFS
Median, months 5.7
Cumulative at 5 months,% 84.6
TLC: Total leukocytic count, Hb: hemoglobin, BM blasts: bone
marrow blasts, FLT3-ITD: FLT3 internal tandem duplication, FLT-
3-TKD, Tyrosine kinase domain, CR: complete remission, RD,
resistant disease, ID: induction death, OS: overall survival, DFS:
disease free survival.
Fig. 1. PCR-RFLP for DMT3A R882H mutation. Lane 1 showing wild sample with
two bands at 114 bp and 190 bp. Lanes 2,3 and 4 showing positive samples with
three bands at 114 bp, 190 bp, and 289 bp.
Fig. 2. Qualitative ASB-PCR showing Ct difference between wild and mutant cases.
Fig. 3. Analysis of ASB-PCR specificity using sanger sequencing. The arrow is
pointing to the mixed peak G > A.
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PCR-RFLP. The mean and median Ct-value for mutant and wild
cases was (25.7/26 versus 33.6/34 respectively, p value = 0.001),(Fig. 2). All positive cases were confirmed by sanger sequencing
(Fig. 3).
The frequency of DNMT3A was detected in 7/56 (12.5%) of
patients. The mean age of patients with positive mutations tends
to higher when compared to the mutation negative group (wild-
type) (47 ± 7.3 vs 38.5 ± 12, p = 0.08). No association was found
with initial laboratory parameters, including FLT3-ITD (p = 1),
(Table 2).
3.3. Response to induction chemotherapy
Forty-five (45/56, 80.3%) patients were followed for 28 days,
29/56 (51.8%) patients achieved CR, and 16/56 (28.6%) had RD. Ele-
ven patients 11/56 (19.6%) died during induction chemotherapy
(ID). DNMT3A R882H mutation positive patients did not show sta-
tistical different response to induction chemotherapy when com-
pared to the wild-type group (20% vs 79.3, p = 0.2), (Table 2).
3.4. Survival analysis
The median follow-up period for the whole group was 1.6 (0–
11.7) months. The cumulative OS at 6 months was 65%, and DFS
was 84%. DNMT3A mutation had no effect on the OS and DFS
(100% vs 60%, p = 0.09 and 80% vs 85%; p = 0.59 respectively),
(Table 2).
4. Discussion
In the present study, we identified DNMT3A R882H mutations in
12.5% of patients with M3 negative de novo AML. This frequency is
very close to that (13%) reported by other studies, [12]. Higher fre-
quency (27%) of DNMT3Amutation could be attributed to the selec-
tion of specific cytogenetic subgroups such as CN-AML versus a
cohort of a non-AML M3 group in our study [15,16]. DNMT3A
mutations are frequently associated with intermediate risk cytoge-
Table 2






Mean age (years) 38.5 ± 12 47 ± 7.3 0.08
Sex, n (%)
Male 25 (51) 3 (42.9)
Female 24 (49) 4 (57.1) 1
Mean TLCx109/L 58.42 ± 69.77 36.25 ± 47.06 0.42
Mean HGB (g/dl) 7.09 ± 1.72 7.31 ± 2.20 0.76
Mean PLTx109/L 64.65 ± 58.43 72.5 ± 73.6 0.36
Mean BM blasts n (%) 52.67 ± 26.89 54.57 ± 28.31 0.87
Hepatomegaly, n (%) 10 (20.4) 3 (42.9) 0.34
Splenomegaly, n (%) 4 (8.2) 2 (28.6) 0.16
Lymphadenopathy, n(%) 7 (14.3) 1 (14.3) 1
FLT3-ITD, n (%)
Wild 39 (79.6) 5 (71.4)
Mutant 10 (20.4) 2 (28.6) 1
FLT3-TKD, n (%)
(n = 53)
Wild 43 (91.5) 4 (8.5) 1
Mutant 6 (100) 0
FAB subtypes, n (%)
M1 + M2 24 (85.7) 4 (14.3)
M4 + M5 20 (90.9) 2 (9.1)
Response to induction
CR 23 (79.3) 6 (20.7)
RD 15 (93.8) 1 (6.3) 0.2
ID 11 (100) 0
OS
Cumulative 60 100 0.09
DFS
Cumulative 85 80 0.59
TLC: Total leukocytic count, Hb: hemoglobin, BM blasts: bone marrow blasts, FLT3-
ITD: FLT3 internal tandem duplication, FLT-3-TKD, Tyrosine kinase domain, CR:
complete remission, RD, resistant disease, ID: induction death, OS: overall survival,
DFS: disease free survival.
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in adverse cytogenetic, and rare in cytogenetically low risk group
[17]. In addition, we have found a tendency of DNMT3AR882H
mutation to increase with age, (p = 0.08). This finding was consis-
tent with previous studies [18,19]. Whereas, no association was
found with initial laboratory parameters including WBC, HGB
and BM blasts (p > 0.05) supporting the previous findings [20–22].
With respect to AML FAB subtypes, like previous studies
[22,23], we were not able to find an association of DNMT3A muta-
tion with a with specific FAB subtype. However, other studies
[9,22,23] reported an association between FAB M4 and M5 and
DNMT3A mutations.
Previous studies demonstrated an association between DNMT3A
mutation with FLT3-ITD mutation [9,24,25]. These molecular asso-
ciations between DNMT3A and FLT3-ITD were frequently detected
in patients with CN-AML [17]. The selection of non-AML M3
patient cohort in this study, could be the main factor behind the
lack of association. Similar results were previously observed [15].
In addition, the characterization of DNMT3A mutation with high
WBC count and the FAB M5 and M4 subtypes can be attributed
to the frequent co-occurrence of DNMT3A mutation with the
FLT3-ITD mutation which is usually presented with these two lab-
oratory features [10]. Besides, the association between DNMT3A
R882 mutation with NPM1 mutation could be a part of the associ-
ation between FLT3-ITD and NPM1 [2,17].
The effect of DNMT3A R882 mutation on response to induction
chemotherapy and survival showed confusing results in the litera-
ture. In accordance with most of the studies [10,15–6,22], we have
found no significant influence of DNMT3A R882H mutation on the
response to induction chemotherapy. In contrast, Gaidzic et al. [17]
found a slightly favorable outcome for patients carrying the muta-
tion (p = 0.058) in an entire AML cohort. However, it was affectedby the distribution of the mutation among cytogenetics of sub-
groups and not linked to the mutation [15]. On the other hand,
Thol et al. [19] described inferior response to induction chemother-
apy in DNMT3A positive patients compared to wild-type.
When we revised the published literature on the effect of
DNM3A mutations on patient’s survival, we have found a very con-
tradicting results. However, they agreed on the effect of age, coex-
isting molecular alterations such as FLT3-ITD and NPM1 and
cytogenetic subgroups. In this work, we found no significant effect
for DNMT3A R882H mutation on OS or DFS. This finding was sup-
ported by previous studies [5,17,24]. In contrast, other studies
[8,22,25,26] found a highly significant inferior outcome for
DNMT3A R882 mutation.
In this work, we used the most common molecular techniques,
ASB-PCR and PCR-RFLP methods for the detection of DNMT3A
R882Hmutation. Both techniques showed 100% concordance. ASB-
PCR was more reliable when compared to endonuclease restriction
for the detection of the mutation. However, both methods are easy
to interpret when used for the initial screening of AML patients.
Analysis of DNMT3A effect on patient’s outcome in this study
was limited by the small number of patients positive for the muta-
tion, short follow-up period and testing for only the R882H type of
mutations. The reason behind the death of 19.6% of our group of
patients before the end of induction chemotherapy (ID) should
be investigated thoroughly in future studies.
In conclusion, the DNMT3A R882H is a frequent mutation in de
novo AML and tends to increase with age. Endonuclease restriction
is a useful tool for detection of DNMT3A R882H mutation in AML.
However, ASB-PCR is more rapid and could be used for quantita-
tion of MRD after induction chemotherapy. Larger sample size
and homogenous cytogenetics and molecular group are recom-
mended for the study of the prognostic effect DNMT3A R882H
mutation on AML patient’s outcome.Acknowledgments
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